Shaw Watanabe1, Shoichi Mizuno1, Li-Hwa Oshima1, Yukiko Tsunematsu2, Junichiro Fujimoto2 and Atsushi Komiyama3 Leukemia Study Group of the Foundation for Growth Science, Japan l Epidemiology Division, National Cancer Center; 2 Hemato-Oncology Division and Research Institute, National Children's Hospital, 3 Department of Pediatrics, Shinshu University, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104, Japan SYNOPSIS The number of reported cases of leukemia ieveloping in growth hormone (GH) users /orldwide has reached 31. Twelve Japanese ases are briefly reviewed; five each of AML and ÃLL, and one each of CML and malignant hisiocytosis. The underlying diseases of these >atients consisted of 8 idiopathic disease, 3 umors and one Fanconi's anemia. Leukemia >ccurred during GH treatment in 9 cases and titer cessation of GH in 3. The longest interval rom the cessation of GH therapy was 10 years. jH administration from a younger age tended Î¿ be linked to myeloid type: Risk factors and possible mechanisms of leukemogenesis by growth hormone are discussed, and proposals or the future have been made by the Foundation or Growth Science in Japan. INTRODUCTION Administration of growth hormone is inavoidable for the treatment of pituitary Iwarfism. Although a risk of leukemia has been predicted based on experiments in
Journal of Pediatric Endocrinology and Metabolism – de Gruyter
Published: Jan 1, 1993
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera